Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
28.72
-0.32 (-1.10%)
May 30, 2025, 2:52 PM - Market open
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Xenon Pharmaceuticals stock ranges from a low of $47 to a high of $67. The average analyst price target of $54.82 forecasts a 90.88% increase in the stock price over the next year.
Price Target: $54.82 (+90.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xenon Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 3 | 4 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 7 | 7 | 8 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +91.50% | May 14, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $47 | Buy | Maintains | $50 → $47 | +63.65% | May 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $58 → $55 | Buy | Maintains | $58 → $55 | +91.50% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $53 | Strong Buy | Reiterates | $53 | +84.54% | May 13, 2025 |
| Needham | Needham | Strong Buy Maintains $60 → $55 | Strong Buy | Maintains | $60 → $55 | +91.50% | May 13, 2025 |
Financial Forecast
Revenue This Year
4.18M
Revenue Next Year
29.70M
from 4.18M
Increased by 611.23%
EPS This Year
-4.11
from -3.01
EPS Next Year
-4.66
from -4.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.4M | 169.3M | 318.5M | ||
| Avg | 4.2M | 29.7M | 121.7M | ||
| Low | n/a | n/a | 29.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 3,952.9% | 972.5% | ||
| Avg | - | 611.2% | 309.6% | ||
| Low | - | - | -2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.36 | -3.39 | -1.22 | ||
| Avg | -4.11 | -4.66 | -4.22 | ||
| Low | -4.41 | -5.63 | -5.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.